SRRK
NASDAQ
$50.66
Scholar Rock Holding Corp (SRRK)
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $59.31 (+17.07%)
Market Cap
$6.44B
FCF 5Y CAGR
+26.01%
Free Cash Flow Yield
-4.72%
Beta (5Y)
0.67
Price Chart
Valuation
Market Cap$6.44B
P/S13.14
P/B23.35
Profitability
Gross Profit (TTM)-$212M
EBITDA-$408M
Profit Margin-23.9%
Operating Margin-20.9%
EPS-$3.90
Financial Health
Debt-to-Equity71.2%
Free Cash Flow Yield-4.72%
Growth & Risk
EPS 5Y CAGR+5.29%
FCF 5Y CAGR+26.01%
Beta (5Y)0.67
Sharpe Ratio0.51